Search clinical trials for: SPH5030

Total 17 results

Shanghai Pharmaceuticals Holding Co., Ltd

Not yet recruiting

A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.

Biliary Tract or Colorectal Cancer With Her2-positive/Mutated

China
Shanghai Pharmaceuticals Holding Co., Ltd

Completed

A Food Effect Study of SPH5030 Tablets.

Advanced Solid Tumor

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

HER2-positive Advanced Solid Tumors

China
Shire

Completed

Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17

Attention Deficit Disorder With Hyperactivity
Shire

Completed

Safety and Efficacy of SPD503 in Treating Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-17

Attention Deficit Disorder With Hyperactivity
Shire

Completed

Efficacy and Safety of SPD503 in Combination With Psychostimulants

ADHD

United States
Shire

Completed

Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

Attention Deficit Hyperactivity Disorder (ADHD)

Spain, Germany, Ukraine, France, Italy, Austria, Belgium, Ireland, Netherlands, Poland, Romania, Sweden, United Kingdom
Shire

Completed

A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers

Healthy

United States
Maastricht University Medical Center
Shire

Completed

Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity (SPD503-315)

Attention Deficit Disorder

Netherlands
Shire

Completed

A Drug Interaction Study of SPD503 and Vyvanse Administered Alone and In Combination in Normal Healthy Volunteers

Healthy

United States
Shire

Completed

Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Disorder With Hyperactivity
Shire

Completed

SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms

ADHD

United States
Shire

Completed

Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17

Attention Deficit Disorder With Hyperactivity
Shire

Completed

SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)

Phobia, Social | Anxiety, Separation | Generalized Anxiety Disorder (GAD)

United States
Children's Specialized Hospital
Shire

Terminated

Effect of Guanfacine Extended-Release on Attention Deficit Hyperactivity Disorder (ADHD)-Associated Insomnia

Insomnia | Sleep Disorders | Attention-Deficit/Hyperactivity Disorder | Attention Deficit Disorder

United States
Shire

Completed

Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)

Attention-Deficit/Hyperactivity Disorder

United States, Canada
Shire
Takeda Development Center Americas, Inc.

Recruiting

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, United States, United Kingdom, Belgium, Germany, Netherlands, Portugal, Austria, Sweden

3

Subscribe